This presentation, showcased as a poster at ASCPT 2025, delves into the transformative potential of monoclonal antibodies (mAbs) in modern medicine. While mAbs have revolutionized the treatment of diseases with their high potency, specificity, and convenient dosing, there remains a gap in demonstrating the predictive value of pharmacokinetic/pharmacodynamic (PK/PD) models in clinical dose-response predictions.
Using dupilumab, a groundbreaking mAb approved for atopic dermatitis, asthma, and other type 2 inflammatory diseases, as a case study, this work explores how a minimal physiologically based PK/PD (mPBPK) model was developed to predict receptor occupancy and correlate it with clinical efficacy. The findings underscore the power of innovative modeling techniques to optimize dose selection and improve therapeutic outcomes.
This cutting-edge research opens doors to advancements across diverse diseases and treatments. Don’t miss the opportunity to explore this groundbreaking work, watch the full presentation below.
Request a Proposal
Share This
